UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013921
Receipt number R000015659
Scientific Title Efficacy of ipragliflozin on glucose metabolism
Date of disclosure of the study information 2014/05/16
Last modified on 2014/10/25 23:30:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of ipragliflozin on glucose metabolism

Acronym

Efficacy of ipragliflozin on glucose metabolism

Scientific Title

Efficacy of ipragliflozin on glucose metabolism

Scientific Title:Acronym

Efficacy of ipragliflozin on glucose metabolism

Region

Japan


Condition

Condition

type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

to investigate the change of glucose metabolism after the treatment with ipragliflozin in type 2 diabetic patients with poor glycemic control

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of glucose metabolism assessed by a 75-g oral glucose tolerance test

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

treatment with ipragliflozin

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

type 2 diabetic patients with poor glycemic control

Key exclusion criteria

- severe hepatic, renal, and/or cardiac diseae
- contraindication to ipragliflozin
- pregnant or breast-feeding females

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshihiko Shiraiwa/Taka-aki Matsuoka

Organization

Shiraiwa Medical Clinic/Osaka University Graduate School of Medicine

Division name

-/Dept of Metabolic Medicine

Zip code


Address

4-10-24, Hozenji, Kashiwara, Osaka, Japan/2-2, Yamadaoka, Suita, Osaka, Japan

TEL

072-971-1221

Email

shiraiwa@endmet.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mitsuyoshi Takahara

Organization

Osaka University Graduate School of Medicine

Division name

Dept of Metabolic Medicine

Zip code


Address

2-2, Yamadaoka, Suita, Osaka, Japan

TEL

06-6879-3743

Homepage URL


Email

takahara@endmet.med.osaka-u.ac.jp


Sponsor or person

Institute

Shiraiwa Medical Clinic

Institute

Department

Personal name



Funding Source

Organization

Astellas Pharma Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Dept of Metabolic Meidicine, Osaka University Graduate School of Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

白岩内科医院(大阪府)


Other administrative information

Date of disclosure of the study information

2014 Year 05 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 16 Day

Date of IRB


Anticipated trial start date

2014 Year 05 Month 16 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 05 Month 09 Day

Last modified on

2014 Year 10 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015659


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name